Chiesi Farmaceutici SpA has synthesized new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Vicore Pharma AB has divulged new angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of rheumatoid arthritis, diabetic nephropathy, pulmonary arterial hypertension, myocardial infarction, pneumonia viral, sarcoidosis, idiopathic pulmonary fibrosis and systemic scleroderma (systemic sclerosis), among other disorders.
Bolt Biotherapeutics Inc. has presented new 2-amino-4-carboxamide-benzazepine antibody-drug conjugates (ADCs) comprising antibodies covalently linked to TLR7 and/or TLR8 agonists through a linker and reported to be useful for the treatment of cancer.
Bioage Labs Inc. has synthesized new NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndromes, hearing loss, Ménière's disease, tinnitus, vertigo and inflammatory disorders.
Columbia University has presented non-hallucinogenic ariadne analogues acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression, among other disorders.
Cadent Therapeutics Inc. and Novartis AG have described cyclopental[c]pyrrol glutamate receptor ionotropic, NMDA 2B (GRIN2B; GluN2B) negative allosteric modulators reported to be useful for the treatment of pain, autism, tinnitus, anxiety disorders, Rett syndrome, Parkinson's disease, migraine and major depression.
Sumitomo Pharma Oncology Inc. has patented (furopyrimidin-4-yl)piperazine compounds acting as DNA repair protein RAD51 homolog 1 (RAD51) expression inhibitors reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has presented new pyrimidine derivatives acting as leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of neurodegeneration.
Jacobio Pharmaceuticals Co. Ltd. has identified new stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer.
The Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO) has presented new imidazo[1,2-b]pyridazine-based tricyclic compounds acting as serine/threonine-protein kinase haspin (GSG2) inhibitors and reported to be useful for the treatment of cancer.
RSS